机构:[1]Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China浙江省肿瘤医院[2]Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[3]Department of thoracic surgery, Fourth Hospital of Hebei Medical University & Hebei Cancer Hospital, Shijiazhuang, China河北医科大学第四医院[4]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University & Hebei Cancer Hospital, Shijiazhuang, China河北医科大学第四医院[5]Department of Radiation Oncology, Hebei University Affiliated hospital, Baoding, China河北大学附属医院[6]Department of CT/MRI, Fourth Hospital of Hebei Medical University & Hebei Cancer Hospital, Shijiazhuang, China河北医科大学第四医院
To analyze the factors contributing to recurrence in patients with pT3N0M0 thoracic esophageal squamous cell carcinoma (ESCC).
Patients with pT3N0M0 thoracic ESCC who underwent esophagectomy from January 2008 to December 2012 were included retrospectively. The last date of follow-up was 1 December 2016. Multivariate proportional hazard Cox models were used to identify factors associated with total (i.e., any) recurrence (TR), locoregional recurrence (LR), and distant metastasis (DM).
A total of 692 patients were included. The median follow-up was 53 months (range: 3-107). The 3- and 5-year TR, LR, and DM rates were 35.8% and 41.0%, 28.7% and 32.1%, and 16.8% and 21.1%, respectively. The Cox analyses showed that the tumor location, number of dissected lymph nodes, and postoperative therapies were significantly associated with LR. The subgroup analysis showed that postoperative therapies could significantly decrease LR in the mediastinum but not in the neck and upper abdomen regions.
The recurrence rate of pT3N0M0 thoracic ESCC patients was high, especially for LR in the mediastinum. Postoperative therapies can significantly reduce the incidence of mediastinal recurrence.
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|4 区医学
小类|4 区医学:研究与实验4 区药学
最新[2025]版:
大类|4 区医学
小类|4 区医学:研究与实验4 区药学
JCR分区:
出版当年[2020]版:
Q4PHARMACOLOGY & PHARMACYQ4MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q4MEDICINE, RESEARCH & EXPERIMENTALQ4PHARMACOLOGY & PHARMACY
第一作者机构:[1]Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China[2]Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China
通讯作者:
通讯机构:[4]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University & Hebei Cancer Hospital, Shijiazhuang, China[*1]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, No. 12, Jiankang road, Shijiazhuang, Hebei Province 050011, China.
推荐引用方式(GB/T 7714):
Feng Wei,Qi Zhan,Qiu Rong,et al.Risk factors for tumor recurrence in patients with pT3N0M0 thoracic esophageal squamous cell carcinoma after esophagectomy.[J].JOURNAL OF INTERNATIONAL MEDICAL RESEARCH.2020,48(12):300060520977403.doi:10.1177/0300060520977403.
APA:
Feng Wei,Qi Zhan,Qiu Rong,Li Zhen-Sheng,Dong Shi-Lei...&Wang Yu-Xiang.(2020).Risk factors for tumor recurrence in patients with pT3N0M0 thoracic esophageal squamous cell carcinoma after esophagectomy..JOURNAL OF INTERNATIONAL MEDICAL RESEARCH,48,(12)
MLA:
Feng Wei,et al."Risk factors for tumor recurrence in patients with pT3N0M0 thoracic esophageal squamous cell carcinoma after esophagectomy.".JOURNAL OF INTERNATIONAL MEDICAL RESEARCH 48..12(2020):300060520977403